ONC — Oncolytics Biotech Share News
0.000.00%
Last trade - 00:00- CA$138.32m
- CA$123.56m
Brief: Oncolytics Biotech Reports Third Quarter Financial Results
Brief: Oncolytics Biotech Reports Interim Results From Phase 1/2 Goblet Study
Brief: Oncolytics Biotech® Appoints Jonathan Rigby To Its Board Of Directors
Brief: Oncolytics Biotech® reports Q2 results
Brief: Oncolytics Biotech Achieves Success Criteria For Efficacy In The Pancreatic Cancer Cohort Of Goblet
Brief: Oncolytics Biotech Achieves Success Criteria For Efficacy In The Pancreatic Cancer Cohort Of Goblet
Brief: Oncolytics Biotech® Reports First Quarter 2022 Financial Results
Brief: Oncolytics Biotech, Solti Present New Clinical Data Demonstrating Pelareorep's Potential To Improve The Prognosis Of Breast Cancer Patients
Brief: Oncolytics Biotech Announces Publication Of Preclinical Data On Pelareorep Combined With Car T Cell Therapy
Brief: Oncolytics Biotech Provides Positive Safety Update On The Third-Line Metastatic Colorectal Cancer Cohort Of Its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Brief: Oncolytics Biotech Partner Adlai Nortye Advances Chinese Bridging Trial Of Pelareorep-Paclitaxel Combination Treatment In Breast Cancer To Final Dosing Cohort
Brief: Oncolytics Biotech Announces Publication Of Preclinical, Patient Data Demonstrating Pelareorep's Stimulation Of Natural Killer Cell Anti-Cancer Activity
Brief: Oncolytics Biotech Announces Publication Of Preclinical, Patient Data Demonstrating Pelareorep's Stimulation Of Natural Killer Cell Anti-Cancer Activity
Brief: Oncolytics Biotech Announces Publication Of Preclinical, Patient Data Demonstrating Pelareorep's Stimulation Of Natural Killer Cell Anti-Cancer Activity
Brief: Oncolytics Biotech Announces Data Demonstrating Proof-Of-Concept For Pelareorep-Proteasome Inhibitor Combination
Brief: Oncolytics Biotech Posts Q4 Loss Per Share Of C$0.14
Brief: Oncolytics Biotech Provides Positive Safety Update On Phase 1/2 Gastrointestinal Cancer Trial
Brief: Oncolytics Biotech® Partner Adlai Nortye Advances To The Second Dose Escalation Cohort Of The Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment In Breast Cancer
Brief: Oncolytics Biotech Promotes Thomas Heineman To Chief Medical Officer